SIRT1 and metabolic disease: Accumulated evidence show that, under metabolic disorder conditions, intracellular NAD+ levels decreased in metabolic tissues, including the liver, adipose tissue, skeletal muscle, which is associated with decreased activation of SIRT1, a NAD+-dependent deacetylase [41,42].